期刊
SCIENCE
卷 375, 期 6584, 页码 1041-+出版社
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.abn2688
关键词
-
资金
- Swedish Research Council [2020-06235, 2021-04665, 2020-05782]
- SciLifeLab National COVID-19 Research Program - Knut and Alice Wallenberg Foundation [VC-20200015]
- SciLifeLab/KAW [VC-2021-0026]
- Swedish Research Council [2021-04665, 2020-06235, 2020-05782] Funding Source: Swedish Research Council
Heterologous prime-boost immunization strategies have the potential to enhance the efficacy of COVID-19 vaccines. A study found that heterologous vaccination induced stronger neutralizing antibody and memory B cell responses, as well as better efficacy against variant strains. The study also revealed that heterologous vaccination can enhance the quality of B cell responses.
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy. We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-specific serological and memory B cell (MBC) responses in individuals who received either homologous (ChAdOx1:ChAdOx1) or heterologous (ChAdOx1:mRNA-1273) prime-boost vaccination. Heterologous messenger RNA (mRNA) booster immunization induced higher serum neutralizing antibody and MBC responses against SARS-CoV-2 variants of concern (VOCs) compared with that of homologous ChAdOx1 boosting. Specificity mapping of circulating B cells revealed that mRNA-1273 boost immunofocused ChAdOx1-primed responses onto epitopes expressed on prefusion-stabilized S. Monoclonal antibodies isolated from mRNA-1273-boosted participants displayed overall higher binding affinities and increased breadth of reactivity against VOCs relative to those isolated from ChAdOx1-boosted individuals. Overall, the results provide molecular insight into the enhanced quality of the B cell response induced after heterologous mRNA booster vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据